干细胞动员剂短期治疗诱导嵌合移植可使得肾移植无需免疫抑制而长期存活:一项小鼠中的研究

Chimeric Allografts Induced by Short-Term Treatment With Stem Cell–Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats
2016-09-29 07:06发表评论
作者:Hu, X., Okabayashi, T., Cameron, A.M., Wang, Y., Hisada, M.ad, Li, J., Raccusen, L.C., Zheng, Q., Montgomery, R.A., Williams, G.M., Sun, Z.
机构: 首都医科大学附属北京朝阳医院泌尿科
期刊: AM J TRANSPLANT2016年7月7期16卷

Transplant tolerance allowing the elimination of lifelong immunosuppression has been the goal of research for 60 years. The induction of mixed chimerism has shown promise and has been extended successfully to large animals and to the clinic; however, it remains cumbersome and requires heavy early immunosuppression. In this study, we reported that four injections of AMD3100, a CXCR4 antagonist, plus eight injections of low-dose FK506 (0.05 mg/kg per day) in the first week after kidney transplantation extended survival, but death from renal failure occurred at 30–90 days. Repeating the same course of AMD3100 and FK506 at 1, 2 and 3 mo after transplant resulted in 92% allograft acceptance (n = 12) at 7 mo, normal kidney function and histology with no further treatment. Transplant acceptance was associated with the influx of host stem cells, resulting in a hybrid kidney and a modulated host immune response. Confirmation of these results could initiate a paradigm shift in posttransplant therapy.

© Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons

通讯机构:Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
学科代码:肾脏病学 外科学   关键词:干细胞动员剂 诱导嵌合移植 肾移植 ,中国作者重要发表 爱思唯尔医学网, Elseviermed
来源: Scopus
Scopus介绍:Scopus 于2004年11月正式推出,是目前全球规模最大的文摘和引文数据库。Scopus涵盖了由5000多家出版商出版发行的科技、医学和社会科学方面的18,000多种期刊,其中同行评审期刊16,500多种。相对于其他单一的文摘索引数据库而言,Scopus的内容更加全面,学科更加广泛,特别是在获取欧洲及亚太地区的文献方面,用户可检索出更多的文献数量。通过Scopus,用户可以检索到1823年以来的近4000万条摘要和题录信息,以及1996年以来所引用的参考文献。数据每日更新。 马上访问Scopus网站http://www.scopus.com/
顶一下(0
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录